August 23, 2025 • 22 mins
Dr. Robert Jackson tackles the controversial yet increasingly compelling topic of repurposed drugs in cancer treatment, sharing remarkable patient stories that challenge conventional medical thinking.
Meet the bladder cancer patient given no hope by her oncologist who achieved complete remission through mistletoe injections. Learn about Joe Tippin, the sole survivor in a lung cancer study who credits mebendazole—an inexpensive anti-parasitic medication—for his recovery. Perhaps most striking is the case of a terminal gallbladder cancer patient told to "get his affairs in order" who showed no evidence of disease after taking ivermectin, mebendazole, and vitamin D3.
While acknowledging the limitations of anecdotal evidence, Dr. Jackson examines emerging clinical data supporting these approaches. The CUSP9 study using nine repurposed drugs showed 30% of glioblastoma patients disease-free after four years—dramatically better than the 5-10% typical with standard care. The METRICS study achieved 64% two-year survival in advanced glioblastoma using four common medications repurposed for cancer treatment.
Dr. Jackson doesn't just talk the talk. When facing a suspected kidney cancer diagnosis himself, he immediately started taking mebendazole while awaiting surgery. "What have you got to lose?" he asks, noting these medications provide an affordable margin of safety alongside conventional treatments.
Are pharmaceutical companies avoiding research into these approaches because there's no profit in off-patent medications? Why aren't more oncologists exploring these options? Listen now to this thought-provoking episode that might just change how you think about cancer treatment options.
https://www.jacksonfamilyministry.com
https://bobslone.com/home/podcast-production/
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:04):
Welcome to More Than Medicine, where Jesus is more
than enough for the ills thatplague our culture and our
country.
Hosted by author and physician,dr Robert Jackson, and his wife
Carlotta and daughter HannahMiller.
So listen up, because thedoctor is in.
Speaker 2 (00:22):
Welcome to More Than Medicine.
I'm your host, dr RobertJackson, bringing to you
biblical insights and storiesfrom the country doctor's rusty,
dusty scrapbook.
Well, rather than interviewingsomeone about today's topic, I
decided that I would share withyou my own personal insights.
And the question for today iswhat about repurposed drugs in
(00:46):
treating cancer?
Increasingly, I have my ownpatients asking for repurposed
drugs for treatment of cancerSome years.
Well, let's see.
One year ago, in 2024, one of mypatients came to me.
One year ago in 2024, one of mypatients came to me and told me
that she had metastatic bladdercancer, that it spread to many
(01:10):
parts of her body and heroncologist had really told her
that he didn't have anythingmore to offer her.
She asked me to refer her to anintegrative oncologist in
Atlanta who I really did notknow at the time, and I agreed
(01:31):
to do so, and then I did not seeher for eight months.
The next time I saw her, eightmonths later, she had regained
all of the weight that she hadlost.
She was feeling better than shehad felt in two years and she
had recently gone to heroncologist, who performed a
repeat PET scan and there was noevidence of cancer in her body.
(01:57):
I was amazed and I was veryimpressed at how she had
regained the health and theweight that she had lost.
Well, she was radiant and shewas very thankful that I was
willing to refer her to anintegrative oncologist that I
didn't even know.
She was so thankful.
(02:19):
Well, that was amazing to me.
And she told me that he hadtreated her with mistletoe
injections.
Well, I did a little researchon that and it turns out
mistletoe is used in Europeextensively for treating cancer.
Well, I had never heard of that.
I had never heard of that inthe United States, and she had
(02:42):
done quite well with themistletoe injections.
Well, fast forward a little bitand in early 2024, I read about
a man named Joe Tippin and hehad broadcast his story on the
internet.
He was one of multiple peoplein a lung cancer study and
(03:04):
everybody in the study diedexcept for Joe Tippin.
Turns out, a friend of Joe'shad recommended that he take
Mabindazole, which is ananti-parasite drug, and he was
the only one in the study whosurvived.
Well, joe shared that with hisdoctors.
Joe shared that with hisdoctors.
(03:29):
They were not impressed, andJoe was incensed that they were
not excited that he had survivedbecause of taking Mabindazole.
Well, mabindazole is aninexpensive drug and Joe
realized quickly that thesedoctors were not impressed
because there was no money in itfor them.
Treating cancer with a drugthat you can acquire at tractor
supply represented no financialincentive for them, and Joe
(03:54):
became quite upset by that andhe broadcast it on the Internet,
and shortly thereafter, dozensof people began to respond to
his website with similar successstories.
Well, I hid that under my hatbecause it didn't represent a
randomized control trial.
(04:15):
As you know, doctors rely onrandomized control trials as
their gold standard in medicine,and these were all anecdotal
stories, and I'm sure there werepeople out there who tried his
protocol and for them it was notsuccessful.
(04:36):
So I was a little bit skeptical.
Well, fast forward a little bitfurther and one of my patients
came into my office in Januaryof 2025.
She was crying, weeping andtelling me that her
brother-in-law, who lived up inI can't remember but New
(04:56):
Hampshire or Vermont, and he hadmetastatic gallbladder cancer
and his doctors had told him togo home and get his affairs in
order.
They didn't have anything elseto offer him, so I just told her
.
I said well, he's got nothingto lose.
Why doesn't he try ivermectinand mabendazole and high-dose
(05:20):
vitamin D3?
Well, she grasped onto that.
She immediately called herbrother-in-law.
He was an engineer so he had toresearch it extensively before
he would agree to try it.
But then he did and I didn'thear anything more for three
months.
She came back to see me for aroutine follow-up in March and
(05:42):
when I saw her, the first wordsout of her mouth was this she
said Dr Jackson, you saved mybrother-in-law's life.
And I said well, what do youmean?
And she said well, he wasskeptical, he had to research
everything, but he finallyagreed to take the Mabindazole,
the Ivermectin and the vitaminD3 in the doses that you
(06:06):
recommended.
She said he went back to hisoncologist at the end of March.
He had regained all of hisweight, he felt better than he
had felt in years and when hehad a repeat PET scan it read no
evidence of disease.
His cancer was completely gone.
His oncologist said it was amiracle.
(06:30):
So she said to me you saved hislife.
Well, I'm here to tell you thatI became a believer at that
moment in time.
Now there was no randomizedcontrolled trial, but that one
patient's response to ivermectinand mabendazole and high-dose
(06:51):
vitamin D3, this man who'd beentold to go home and put his
affairs in order.
That success story made me abeliever.
Made me a believer.
Since then, I've seen a fewrandomized controlled trials
with ivermectin, but with only afew patients.
(07:11):
So the strength of evidence isstill poor, but the sheer volume
of anecdotal evidence isbecoming overwhelming.
For example, the Medical Advisorthe June 2025 edition of the
Medical Advisor has an articleentitled Ivermectin Cancer
(07:37):
Success Stories 139 case reports.
And I'm here to tell you thatalmost all of the case reports
are stage 4 metastatic disease.
That means they are hopelesscases.
And yet in three to six monthsafter treatment with ivermectin
(08:03):
and or mabindazole, thesepatients are considered free of
disease.
In other words, their PET scansread no evidence of disease.
And this is remarkable 139cases Now contrast that with the
(08:24):
advice of multiple physiciansin an article published in
PubMed.
Now I'm going to read this.
This is an abstract from thatarticle and it says Pre-clinical
studies, in vitro and animalstudies, demonstrate
ivermectin's anti-cancer effects, including inhibition of cancer
(08:47):
cell proliferation, inductionof apoptosis that's when the
cells implode and modulation ofsignaling pathways across
various cancers.
However, clinical evidence inhumans is limited, with no
large-scale randomizedcontrolled trials.
(09:08):
And all that's true.
That confirms therapeuticbenefits.
Observational studies and casereports highlight the risk of
self-medication driven by socialmedia touting ivermectin's
unproven cancer benefits, whichcan lead to toxicity in oncology
(09:30):
patients in some cases.
The lack of clinical studiescreates a critical translational
gap between pre-clinicalresults and practical clinical
application.
Despite promising pre-clinicaldata, the absence of conclusive
large-scale human clinicalevidence limits the ivermectin's
(09:53):
utility in cancer treatment.
Its affordability appeals inresource-limited settings, and
that's true, because a lot of mypatients cannot afford cancer
therapy which can run into tensof thousands of dollars.
But ethical challenges arisefrom misinformation which may
(10:16):
lead patients to forego proventherapies.
Healthcare providers mustcommunicate responsibly to
counter misinformation and guidepatients toward evidence-based
interventions, which reallymeans standard of care that's
been accepted for a long time,while supporting rigorous
clinical trials to bridge thepreclinical to clinical gap.
(10:39):
Now, every bit of that is true.
Nothing wrong with that, andthat's a cautionary abstract in
PubMed.
Now patients ask me, dr Jackson, what's your advice?
And I get that question.
I bet twice a day in my medicalclinic and I'll tell them it's
(11:00):
too early to tell.
There are insufficientrandomized controlled trials to
validate the effectiveness ofrepurposed drugs like ivermectin
and mabendazole.
The problem is there's nofinancial incentive for
pharmaceutical companies toresearch generic medications
(11:29):
research generic medications.
They're not interested incuring your cancer with cheap
medications that won't linetheir pockets with bukus of cash
.
However, when we keep hearinganecdotal reports of friends and
neighbors who have cured theirlate-stage cancers with a $200
supply of repurposed drugs thatthey can obtain at Tractor
(11:52):
Supply, we can't just ignorethose reports.
My other recommendation is this,and it's a caveat the doctors
on X and the doctors on Facebookaren't telling you about their
patients that failed to improveon their repurposed drug regimen
(12:16):
, and I think that'sdisingenuous.
They're telling you all oftheir success stories, but
they're not telling you abouttheir patients who did not get
well.
To be fully honest, they shouldreport on every patient's
progress, both good and bad.
Nothing cures every cancer notivermectin, not mabindazole, not
(12:41):
chemo, not radiation and noteven faith healers.
Nothing cures all cancers andall of us realize that.
I tell my patients that I'm notan oncologist and that they
should follow their oncologistrecommendations.
They should follow the standardof care treatment for their
(13:02):
cancer, including surgery first,including surgery first, then
chemo and then radiation, orboth.
If they want to add arepurposed drug or drugs plural
then I will help them or I willrefer them to a clinic that
specializes in that kind of carewith repurposed drugs.
(13:22):
Now, just so you will know, andI want you to know about this,
there are two cancer nonprofitorganizations out there One's
called the Anti-Cancer Fund andthe other's the Global Cures
Organization, and they partneredtogether to create the RE-DU
(13:43):
Project, and that stands forRepurposed drugs in oncology.
The REDU project stands for therepurposed drugs in oncology.
Now, the REDU project created adatabase of all published or
planned or active trials ofrepurposed drugs in cancer in
(14:05):
the United States, europe andthe World Health Organization
trial registries, and theyidentified 970 trials in 45
countries.
Although the REDU project hasidentified 970 trials of
repurposed drugs in oncology,unfortunately very few are what
(14:31):
we call actionable, given thatmany were terminated for lack of
enrollment.
Others are still recruiting ortheir recent status is unclear
in the registry.
They were updated but not filed.
They were updated but not filed.
Most disappointing is that thevast majority tested a single
(14:52):
repurposed drug that was addedto the standard of care, and
it's challenging to findpublished results of trials
testing the addition of multipleagents at the same time.
But there are a few, forexample.
I'm going to give you a coupleof examples, and most of these
examples are treatingglioblastoma.
(15:14):
Now why is that?
The reason is that glioblastomais one of the most deadly
cancers and it has a highlypredictable median overall
survival of 15 months and atwo-year survival of 27 percent,
despite standard of care,combinations of surgery, chemo
(15:37):
and radiation and oralmaintenance chemotherapy.
This highly predictable and,quite honestly, terrible
survival allows for comparisonand outcomes between the two
approaches.
Another reason is thatglioblastoma has numerous
mechanisms that drive its growth.
(15:58):
Therefore, it demands acombination of multiple
mechanistic approach, and theresults of the accumulated data
is very impressive.
Now let me give you tworandomized controlled trials
that are out there.
One's called the CUSP C-U-S-P 9study.
(16:18):
It's a repurposed regimen thatuses 1, 2, 3, 4, 5, 6, 7, 8, 9
drugs, and those drugs areaprepotant, orinofen, captopril,
celecoxib, disulfiram,itraconazole, minocycline,
ritanavir and sertraline, andyou'll recognize some of those
(16:41):
names, but all nine of thosedrugs are used at one time to
treat glioblastoma.
A report of their phase onetrial in 2021 showed 30% of
patients were alive anddisease-free at over four years
post-treatment.
Now compare that to historicalprognosis with standard of care
(17:06):
therapies.
To historical prognosis withstandard of care therapies the
long-term disease-free survivalis greater than four years, and
that's extremely rare andtypically occurs in under 5 to
10% of patients, and it's mostlylimited to exceptional
responders.
(17:26):
And yet, in this nine-drugregimen, 30% of the patients
were alive and disease-free atover four years, and so most of
the patients in the standard ofcare only survived four years at
maybe 5%, 10% at the most.
And yet in this program usingnine repurposed drugs, the
(17:51):
survival was 30% at four years.
That's pretty remarkable.
And there's another study calledthe METRICS study, also using
repurposed drugs, published in2019, included 95 patients.
They were all stage fouradvanced glioblastomas.
They were all stage 4 advancedglioblastomas and they used four
(18:13):
drugs metformin, a diabetesmedicine, atorvastatin, a
cholesterol drug, mabindazole,an antiparasitic drug, and
doxycycline, an antibiotic.
Well, the two-year survival forthis regimen was 64%.
That's amazing, that's a doublewow.
(18:36):
So there you go, a repurposeddrug treating glioblastoma.
So I'm just giving you an ideaof how repurposed drugs are
being used to treat cancers Now.
So here's the next thing.
So, dr Jackson, what would youdo?
(18:57):
Now?
That's what my patients, afterwe discuss it, they'll look at
me and say well, dr Jackson,what would you do, knowing what
you know?
What would you do?
Well, I'll be honest.
What would you do?
Well, I'll be honest.
Two years ago I had a kidneystone and the CT scan showed
that I had a 3-centimeter tumoron my right kidney, and so I
(19:24):
ended up having one-third ofthat kidney removed.
In advance, the urologist toldme that I had a renal cell
carcinoma.
We kept asking what's thepossibility?
This is benign.
And he emphatically told me andso did the radiologist this is
a renal cell carcinoma.
So what did I do?
I immediately orderedMabindazole off the internet it
(19:46):
cost me $60, and I began taking200 milligrams of Mabindazole.
And I began taking 200milligrams of Mabindazole.
Now it took six months to getmy surgery scheduled.
Six weeks, I'm sorry, six weeksto get it scheduled.
So for six weeks, thinking thatI had renal cell carcinoma, I
took Mabindazole.
However, after surgery, thepathology showed that I had a
(20:11):
benign tumor, an onchocytoma.
My urologist said in 25 yearshe had never seen an onchocytoma
.
So we thanked the Lord, wethanked my urologist and I quit
taking the Mabendazole because Idid not need it any longer.
So now you know what Dr Jacksonwould do.
(20:34):
When I thought I had a kidneycancer, I started taking
Mabindazole.
So what should you do If youhave a cancer.
What have you got to lose?
For $160 to $200 a month, youcan give yourself a margin of
safety without any danger toyourself.
(20:54):
The ivermectin and themabendazole and the vitamin D3
are very safe medications andthey give you a margin of safety
.
Your chemo and your radiationcost $10,000 or more per month.
What's $200 a month compared tothat?
I wouldn't hesitate and Iwouldn't wait on randomized
(21:19):
control trials to validate theeffectiveness of the Mabindazole
, the Ivermectin, the vitamin D3.
I would hurry up and I wouldrun to the internet and I would
order myself those medicationsand I would start taking them.
What have you got to lose?
It's not going to hurt you andit would certainly give you a
(21:43):
margin of safety.
Well, you're listening to MoreThan Medicine.
I'm your host, dr RobertJackson.
I hope that's been helpful toyou and until next week,
remember that your doctor lovesyou and may the Lord bless you
real good.
Speaker 1 (22:02):
Thank you for listening to this edition of
More Than Medicine.
For more information about theJackson Family Ministry or to
schedule a speaking engagement,go to their Facebook page,
instagram or webpage atjacksonfamilyministrycom.
Also, don't forget to check outDr Jackson's books that are
available on Amazon His thirdbook, turkey Tales and Bible
(22:23):
Truths, and his father'sbiography on Laughter Silvered
Wings the story of a countrydoctor, a family man, a patriot
and a political activist.
This podcast is produced by BobSloan Audio Productions.
Welcome to More Than Medicine, where Jesus is more
than enough for the ills thatplague our culture and our
country.
Hosted by author and physician,dr Robert Jackson, and his wife
Carlotta and daughter HannahMiller.
So listen up, because thedoctor is in.
Speaker 2 (00:22):
Welcome to More Than Medicine.
I'm your host, dr RobertJackson, bringing to you
biblical insights and storiesfrom the country doctor's rusty,
dusty scrapbook.
Well, rather than interviewingsomeone about today's topic, I
decided that I would share withyou my own personal insights.
And the question for today iswhat about repurposed drugs in
(00:46):
treating cancer?
Increasingly, I have my ownpatients asking for repurposed
drugs for treatment of cancerSome years.
Well, let's see.
One year ago, in 2024, one of mypatients came to me.
One year ago in 2024, one of mypatients came to me and told me
that she had metastatic bladdercancer, that it spread to many
(01:10):
parts of her body and heroncologist had really told her
that he didn't have anythingmore to offer her.
She asked me to refer her to anintegrative oncologist in
Atlanta who I really did notknow at the time, and I agreed
(01:31):
to do so, and then I did not seeher for eight months.
The next time I saw her, eightmonths later, she had regained
all of the weight that she hadlost.
She was feeling better than shehad felt in two years and she
had recently gone to heroncologist, who performed a
repeat PET scan and there was noevidence of cancer in her body.
(01:57):
I was amazed and I was veryimpressed at how she had
regained the health and theweight that she had lost.
Well, she was radiant and shewas very thankful that I was
willing to refer her to anintegrative oncologist that I
didn't even know.
She was so thankful.
(02:19):
Well, that was amazing to me.
And she told me that he hadtreated her with mistletoe
injections.
Well, I did a little researchon that and it turns out
mistletoe is used in Europeextensively for treating cancer.
Well, I had never heard of that.
I had never heard of that inthe United States, and she had
(02:42):
done quite well with themistletoe injections.
Well, fast forward a little bitand in early 2024, I read about
a man named Joe Tippin and hehad broadcast his story on the
internet.
He was one of multiple peoplein a lung cancer study and
(03:04):
everybody in the study diedexcept for Joe Tippin.
Turns out, a friend of Joe'shad recommended that he take
Mabindazole, which is ananti-parasite drug, and he was
the only one in the study whosurvived.
Well, joe shared that with hisdoctors.
Joe shared that with hisdoctors.
(03:29):
They were not impressed, andJoe was incensed that they were
not excited that he had survivedbecause of taking Mabindazole.
Well, mabindazole is aninexpensive drug and Joe
realized quickly that thesedoctors were not impressed
because there was no money in itfor them.
Treating cancer with a drugthat you can acquire at tractor
supply represented no financialincentive for them, and Joe
(03:54):
became quite upset by that andhe broadcast it on the Internet,
and shortly thereafter, dozensof people began to respond to
his website with similar successstories.
Well, I hid that under my hatbecause it didn't represent a
randomized control trial.
(04:15):
As you know, doctors rely onrandomized control trials as
their gold standard in medicine,and these were all anecdotal
stories, and I'm sure there werepeople out there who tried his
protocol and for them it was notsuccessful.
(04:36):
So I was a little bit skeptical.
Well, fast forward a little bitfurther and one of my patients
came into my office in Januaryof 2025.
She was crying, weeping andtelling me that her
brother-in-law, who lived up inI can't remember but New
(04:56):
Hampshire or Vermont, and he hadmetastatic gallbladder cancer
and his doctors had told him togo home and get his affairs in
order.
They didn't have anything elseto offer him, so I just told her
.
I said well, he's got nothingto lose.
Why doesn't he try ivermectinand mabendazole and high-dose
(05:20):
vitamin D3?
Well, she grasped onto that.
She immediately called herbrother-in-law.
He was an engineer so he had toresearch it extensively before
he would agree to try it.
But then he did and I didn'thear anything more for three
months.
She came back to see me for aroutine follow-up in March and
(05:42):
when I saw her, the first wordsout of her mouth was this she
said Dr Jackson, you saved mybrother-in-law's life.
And I said well, what do youmean?
And she said well, he wasskeptical, he had to research
everything, but he finallyagreed to take the Mabindazole,
the Ivermectin and the vitaminD3 in the doses that you
(06:06):
recommended.
She said he went back to hisoncologist at the end of March.
He had regained all of hisweight, he felt better than he
had felt in years and when hehad a repeat PET scan it read no
evidence of disease.
His cancer was completely gone.
His oncologist said it was amiracle.
(06:30):
So she said to me you saved hislife.
Well, I'm here to tell you thatI became a believer at that
moment in time.
Now there was no randomizedcontrolled trial, but that one
patient's response to ivermectinand mabendazole and high-dose
(06:51):
vitamin D3, this man who'd beentold to go home and put his
affairs in order.
That success story made me abeliever.
Made me a believer.
Since then, I've seen a fewrandomized controlled trials
with ivermectin, but with only afew patients.
(07:11):
So the strength of evidence isstill poor, but the sheer volume
of anecdotal evidence isbecoming overwhelming.
For example, the Medical Advisorthe June 2025 edition of the
Medical Advisor has an articleentitled Ivermectin Cancer
(07:37):
Success Stories 139 case reports.
And I'm here to tell you thatalmost all of the case reports
are stage 4 metastatic disease.
That means they are hopelesscases.
And yet in three to six monthsafter treatment with ivermectin
(08:03):
and or mabindazole, thesepatients are considered free of
disease.
In other words, their PET scansread no evidence of disease.
And this is remarkable 139cases Now contrast that with the
(08:24):
advice of multiple physiciansin an article published in
PubMed.
Now I'm going to read this.
This is an abstract from thatarticle and it says Pre-clinical
studies, in vitro and animalstudies, demonstrate
ivermectin's anti-cancer effects, including inhibition of cancer
(08:47):
cell proliferation, inductionof apoptosis that's when the
cells implode and modulation ofsignaling pathways across
various cancers.
However, clinical evidence inhumans is limited, with no
large-scale randomizedcontrolled trials.
(09:08):
And all that's true.
That confirms therapeuticbenefits.
Observational studies and casereports highlight the risk of
self-medication driven by socialmedia touting ivermectin's
unproven cancer benefits, whichcan lead to toxicity in oncology
(09:30):
patients in some cases.
The lack of clinical studiescreates a critical translational
gap between pre-clinicalresults and practical clinical
application.
Despite promising pre-clinicaldata, the absence of conclusive
large-scale human clinicalevidence limits the ivermectin's
(09:53):
utility in cancer treatment.
Its affordability appeals inresource-limited settings, and
that's true, because a lot of mypatients cannot afford cancer
therapy which can run into tensof thousands of dollars.
But ethical challenges arisefrom misinformation which may
(10:16):
lead patients to forego proventherapies.
Healthcare providers mustcommunicate responsibly to
counter misinformation and guidepatients toward evidence-based
interventions, which reallymeans standard of care that's
been accepted for a long time,while supporting rigorous
clinical trials to bridge thepreclinical to clinical gap.
(10:39):
Now, every bit of that is true.
Nothing wrong with that, andthat's a cautionary abstract in
PubMed.
Now patients ask me, dr Jackson, what's your advice?
And I get that question.
I bet twice a day in my medicalclinic and I'll tell them it's
(11:00):
too early to tell.
There are insufficientrandomized controlled trials to
validate the effectiveness ofrepurposed drugs like ivermectin
and mabendazole.
The problem is there's nofinancial incentive for
pharmaceutical companies toresearch generic medications
(11:29):
research generic medications.
They're not interested incuring your cancer with cheap
medications that won't linetheir pockets with bukus of cash
.
However, when we keep hearinganecdotal reports of friends and
neighbors who have cured theirlate-stage cancers with a $200
supply of repurposed drugs thatthey can obtain at Tractor
(11:52):
Supply, we can't just ignorethose reports.
My other recommendation is this,and it's a caveat the doctors
on X and the doctors on Facebookaren't telling you about their
patients that failed to improveon their repurposed drug regimen
(12:16):
, and I think that'sdisingenuous.
They're telling you all oftheir success stories, but
they're not telling you abouttheir patients who did not get
well.
To be fully honest, they shouldreport on every patient's
progress, both good and bad.
Nothing cures every cancer notivermectin, not mabindazole, not
(12:41):
chemo, not radiation and noteven faith healers.
Nothing cures all cancers andall of us realize that.
I tell my patients that I'm notan oncologist and that they
should follow their oncologistrecommendations.
They should follow the standardof care treatment for their
(13:02):
cancer, including surgery first,including surgery first, then
chemo and then radiation, orboth.
If they want to add arepurposed drug or drugs plural
then I will help them or I willrefer them to a clinic that
specializes in that kind of carewith repurposed drugs.
(13:22):
Now, just so you will know, andI want you to know about this,
there are two cancer nonprofitorganizations out there One's
called the Anti-Cancer Fund andthe other's the Global Cures
Organization, and they partneredtogether to create the RE-DU
(13:43):
Project, and that stands forRepurposed drugs in oncology.
The REDU project stands for therepurposed drugs in oncology.
Now, the REDU project created adatabase of all published or
planned or active trials ofrepurposed drugs in cancer in
(14:05):
the United States, europe andthe World Health Organization
trial registries, and theyidentified 970 trials in 45
countries.
Although the REDU project hasidentified 970 trials of
repurposed drugs in oncology,unfortunately very few are what
(14:31):
we call actionable, given thatmany were terminated for lack of
enrollment.
Others are still recruiting ortheir recent status is unclear
in the registry.
They were updated but not filed.
They were updated but not filed.
Most disappointing is that thevast majority tested a single
(14:52):
repurposed drug that was addedto the standard of care, and
it's challenging to findpublished results of trials
testing the addition of multipleagents at the same time.
But there are a few, forexample.
I'm going to give you a coupleof examples, and most of these
examples are treatingglioblastoma.
(15:14):
Now why is that?
The reason is that glioblastomais one of the most deadly
cancers and it has a highlypredictable median overall
survival of 15 months and atwo-year survival of 27 percent,
despite standard of care,combinations of surgery, chemo
(15:37):
and radiation and oralmaintenance chemotherapy.
This highly predictable and,quite honestly, terrible
survival allows for comparisonand outcomes between the two
approaches.
Another reason is thatglioblastoma has numerous
mechanisms that drive its growth.
(15:58):
Therefore, it demands acombination of multiple
mechanistic approach, and theresults of the accumulated data
is very impressive.
Now let me give you tworandomized controlled trials
that are out there.
One's called the CUSP C-U-S-P 9study.
(16:18):
It's a repurposed regimen thatuses 1, 2, 3, 4, 5, 6, 7, 8, 9
drugs, and those drugs areaprepotant, orinofen, captopril,
celecoxib, disulfiram,itraconazole, minocycline,
ritanavir and sertraline, andyou'll recognize some of those
(16:41):
names, but all nine of thosedrugs are used at one time to
treat glioblastoma.
A report of their phase onetrial in 2021 showed 30% of
patients were alive anddisease-free at over four years
post-treatment.
Now compare that to historicalprognosis with standard of care
(17:06):
therapies.
To historical prognosis withstandard of care therapies the
long-term disease-free survivalis greater than four years, and
that's extremely rare andtypically occurs in under 5 to
10% of patients, and it's mostlylimited to exceptional
responders.
(17:26):
And yet, in this nine-drugregimen, 30% of the patients
were alive and disease-free atover four years, and so most of
the patients in the standard ofcare only survived four years at
maybe 5%, 10% at the most.
And yet in this program usingnine repurposed drugs, the
(17:51):
survival was 30% at four years.
That's pretty remarkable.
And there's another study calledthe METRICS study, also using
repurposed drugs, published in2019, included 95 patients.
They were all stage fouradvanced glioblastomas.
They were all stage 4 advancedglioblastomas and they used four
(18:13):
drugs metformin, a diabetesmedicine, atorvastatin, a
cholesterol drug, mabindazole,an antiparasitic drug, and
doxycycline, an antibiotic.
Well, the two-year survival forthis regimen was 64%.
That's amazing, that's a doublewow.
(18:36):
So there you go, a repurposeddrug treating glioblastoma.
So I'm just giving you an ideaof how repurposed drugs are
being used to treat cancers Now.
So here's the next thing.
So, dr Jackson, what would youdo?
(18:57):
Now?
That's what my patients, afterwe discuss it, they'll look at
me and say well, dr Jackson,what would you do, knowing what
you know?
What would you do?
Well, I'll be honest.
What would you do?
Well, I'll be honest.
Two years ago I had a kidneystone and the CT scan showed
that I had a 3-centimeter tumoron my right kidney, and so I
(19:24):
ended up having one-third ofthat kidney removed.
In advance, the urologist toldme that I had a renal cell
carcinoma.
We kept asking what's thepossibility?
This is benign.
And he emphatically told me andso did the radiologist this is
a renal cell carcinoma.
So what did I do?
I immediately orderedMabindazole off the internet it
(19:46):
cost me $60, and I began taking200 milligrams of Mabindazole.
And I began taking 200milligrams of Mabindazole.
Now it took six months to getmy surgery scheduled.
Six weeks, I'm sorry, six weeksto get it scheduled.
So for six weeks, thinking thatI had renal cell carcinoma, I
took Mabindazole.
However, after surgery, thepathology showed that I had a
(20:11):
benign tumor, an onchocytoma.
My urologist said in 25 yearshe had never seen an onchocytoma
.
So we thanked the Lord, wethanked my urologist and I quit
taking the Mabendazole because Idid not need it any longer.
So now you know what Dr Jacksonwould do.
(20:34):
When I thought I had a kidneycancer, I started taking
Mabindazole.
So what should you do If youhave a cancer.
What have you got to lose?
For $160 to $200 a month, youcan give yourself a margin of
safety without any danger toyourself.
(20:54):
The ivermectin and themabendazole and the vitamin D3
are very safe medications andthey give you a margin of safety
.
Your chemo and your radiationcost $10,000 or more per month.
What's $200 a month compared tothat?
I wouldn't hesitate and Iwouldn't wait on randomized
(21:19):
control trials to validate theeffectiveness of the Mabindazole
, the Ivermectin, the vitamin D3.
I would hurry up and I wouldrun to the internet and I would
order myself those medicationsand I would start taking them.
What have you got to lose?
It's not going to hurt you andit would certainly give you a
(21:43):
margin of safety.
Well, you're listening to MoreThan Medicine.
I'm your host, dr RobertJackson.
I hope that's been helpful toyou and until next week,
remember that your doctor lovesyou and may the Lord bless you
real good.
Speaker 1 (22:02):
Thank you for listening to this edition of
More Than Medicine.
For more information about theJackson Family Ministry or to
schedule a speaking engagement,go to their Facebook page,
instagram or webpage atjacksonfamilyministrycom.
Also, don't forget to check outDr Jackson's books that are
available on Amazon His thirdbook, turkey Tales and Bible
(22:23):
Truths, and his father'sbiography on Laughter Silvered
Wings the story of a countrydoctor, a family man, a patriot
and a political activist.
This podcast is produced by BobSloan Audio Productions.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com
The Herd with Colin Cowherd
The Herd with Colin Cowherd is a thought-provoking, opinionated, and topic-driven journey through the top sports stories of the day.